Edit |   |
---|---|
Antigenic Specificity | CD22 (Pinatuzumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Pinatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD22, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Pinatuzumab vedotin is under investigation in clinical trial NCT01691898, A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). |
Immunogen | n/a |
Other Names | Pinatuzumab, CD22, 1313706-14-7 |
Gene, Accession # | CAS: 1313706-14-7 |
Catalog # | abx831274 |
Price | please inquire |
Order / More Info | CD22 (Pinatuzumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950